For example, regarding MDM2 inhibition in DDLPS, by virtue of selecting for specific clonal populations with phenotypic features such as inactivating p53 mutations, important questions arise regarding the impact on tumor heterogeneity, sensitivity to cytotoxic therapy, or changes in immunogenicity. The gene discussed is TP53; the disease is neoplasm.